journal article·2021-03-03

68Ga-Labeled Magnetic-NIR Persistent Luminescent Hybrid Mesoporous Nanoparticles for Multimodal Imaging-Guided Chemotherapy and Photodynamic Therapy

Rui Zou, Yifan Gao, Yong Zhang, Ju Jiao, Ka-Leung Wong, Jing Wang

Publisher page

Abstract

Featured with a zero-autofluorescence background, superior signal-to-noise ratio, high sensitivity, and deep penetration ability, near-infrared persistent luminescence nanoparticle (NIR-PLNP)-based multimodal nanoprobes show great potential for full-scale noninvasive cancer diagnosis. However, direct synthesis of NIR-PLNP-based multimodal nanoprobes with high drug loading capacity to meet growing cancer theranostic demands remains a challenge. In this work, multifunctional hybrid mesoporous nanoparticles (HMNPs) that integrate NIR-PLNPs (Ga2O3:Cr3+, Nd3+), magnetic nanoparticles (Gd2O3), and radionuclides (68Ga) are designed and constructed via a large-pore (mesoporous silica nanoparticle) MSN-templated strategy. The ingenious composition design endows HMNPs with rechargeable NIR-PL, superior longitudinal relaxivity, and excellent radioactivity, making these versatile nanoparticles available for long-term in vivo NIR-PL imaging, magnetic resonance imaging (MRI), and positron emission tomography (PET) imaging. More importantly, the application of large-pore MSN templates maintains the mesoporous structure of HMNPs, promising excellent drug loading capacity of these nanoparticles. As a proof-of-concept, HMNPs loaded with a high dose of DOX (chemotherapy agent) and Si-Pc (photosensitizer) are rationally designed for chemotherapy and NIR-PL-sensitized photodynamic therapy (PDT), respectively. Studies with mice tumor models demonstrate that the DOX/Si-Pc-loaded HMNPs possess excellent cancer cell killing ability and an outstanding tumor suppression effect without systemic toxicity. This work shows the great potential of HMNPs as an “all-in-one” nanotheranostic tool for multimodal NIR-PL/MR/PET imaging-guided chemotherapy and NIR-PL-sensitized photodynamic cancer therapy and provides an innovative paradigm for the development of NIR-PLNP-based nanoplatforms in cancer theranostic.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence Properties of Advanced Materials · Lanthanide and Transition Metal Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Nuclear Medicine, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, P.R. China

Ministry of Education Key Laboratory of Bioinorganic and Synthetic Chemistry, State Key Laboratory of Optoelectronic Materials and Technologies, School of Chemistry, Sun Yat-Sen University, Guangzhou, Guangdong 510275, P.R. China

Department of Chemistry, Hong Kong Baptist University, Kowloon Tong 999077, Hong Kong

Funding

Guangdong Science and Technology Department · Research Grants Council, University Grants Committee · Ministry of Education of the People's Republic of China · Guangzhou Science and Technology Program key projects · National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · Guangdong Province · Yunnan Province

References (49)

Show source-provided references
1. 10.1073/pnas.070242710410.1073/pnas.0702427104 ↗
2. 10.7150/thno.1658910.7150/thno.16589 ↗
3. 10.1039/C5CS00582E10.1039/C5CS00582E ↗
4. 10.1038/nmat390810.1038/nmat3908 ↗
5. 10.1021/acsanm.9b0261310.1021/acsanm.9b02613 ↗
6. 10.1016/j.biomaterials.2014.10.03310.1016/j.biomaterials.2014.10.033 ↗
7. 10.1002/advs.20150000110.1002/advs.201500001 ↗
8. 10.1021/acs.accounts.7b0061910.1021/acs.accounts.7b00619 ↗
9. 10.1039/C7NR01488K10.1039/C7NR01488K ↗
10. 10.1021/acs.chemmater.7b0195810.1021/acs.chemmater.7b01958 ↗
11. 10.1039/C7NR01209H10.1039/C7NR01209H ↗
12. 10.1021/acsami.9b1490110.1021/acsami.9b14901 ↗
13. 10.1002/cnma.20190069710.1002/cnma.201900697 ↗
14. 10.1002/smll.20180002010.1002/smll.201800020 ↗
15. 10.1002/adfm.20160499210.1002/adfm.201604992 ↗
16. 10.1021/acs.analchem.6b0044910.1021/acs.analchem.6b00449 ↗
17. 10.1002/adma.20190508710.1002/adma.201905087 ↗
18. 10.1016/j.cej.2020.12713310.1016/j.cej.2020.127133 ↗
19. 10.1002/adfm.20200116610.1002/adfm.202001166 ↗
20. 10.1021/acsami.7b0380210.1021/acsami.7b03802 ↗
21. 10.1002/cnma.20200010110.1002/cnma.202000101 ↗
22. 10.1021/acsami.6b0388110.1021/acsami.6b03881 ↗
23. 10.1007/s40820-019-0263-310.1007/s40820-019-0263-3 ↗
24. 10.1021/acsami.7b1979710.1021/acsami.7b19797 ↗
25. 10.1021/nn200298y10.1021/nn200298y ↗
26. 10.1088/0031-9155/53/4/R0110.1088/0031-9155/53/4/R01 ↗
27. 10.1002/adfm.20140161210.1002/adfm.201401612 ↗
28. 10.1039/C5NR05623C10.1039/C5NR05623C ↗
29. 10.1021/acsami.6b0958010.1021/acsami.6b09580 ↗
30. 10.1021/ac500644x10.1021/ac500644x ↗
31. 10.1002/smll.20140307110.1002/smll.201403071 ↗
32. 10.1039/C5TB02619A10.1039/C5TB02619A ↗
33. 10.1021/acs.chemmater.7b0008710.1021/acs.chemmater.7b00087 ↗
34. 10.1016/j.biomaterials.2017.10.03210.1016/j.biomaterials.2017.10.032 ↗
35. 10.1021/acsami.0c0443810.1021/acsami.0c04438 ↗
36. 10.1039/C7TB03148C10.1039/C7TB03148C ↗
37. 10.1002/adhm.20200080210.1002/adhm.202000802 ↗
38. 10.1039/C7NR02038D10.1039/C7NR02038D ↗
39. 10.1021/nl404316v10.1021/nl404316v ↗
40. 10.1002/adtp.20190006810.1002/adtp.201900068 ↗
41. 10.1016/0022-2313(88)90108-110.1016/0022-2313(88)90108-1 ↗
42. 10.1016/j.jlumin.2011.07.00710.1016/j.jlumin.2011.07.007 ↗
43. 10.1021/am301301f10.1021/am301301f ↗
44. 10.1021/acsnano.7b0760610.1021/acsnano.7b07606 ↗
45. 10.1021/ar500362y10.1021/ar500362y ↗
46. 10.1021/nl503522y10.1021/nl503522y ↗
47. 10.1021/acsnano.6b0768410.1021/acsnano.6b07684 ↗
48. 10.1021/acs.chemmater.7b0346110.1021/acs.chemmater.7b03461 ↗
49. 10.1039/C6CC07616E10.1039/C6CC07616E ↗